Research programme: selective estrogen receptor modulators - SRI International
Alternative Names: SR16158; SR16388Latest Information Update: 04 Nov 2017
At a glance
- Originator SRI International
- Class
- Mechanism of Action Estrogen receptor antagonists; Hypoxia inducible factor 1 inhibitors; Selective estrogen receptor modulators; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (PO)